We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Wearable Sensing Patch Enables Rapid Quantitative Analysis of Urea in Body Fluids

By LabMedica International staff writers
Posted on 24 Feb 2023

Urea, which is excreted in sweat, urine, saliva and blood, is a key indicator of renal function in clinical diagnosis. More...

Effective determination of urea levels can enable early detection of diseases. There has been growing focus on wearable fluorescence-based sensors, although traditional fluorescent hydrogels are excited by short wavelengths, hampering the detection of biological samples. Now, researchers have developed a wearable sensing patch that enables the rapid quantitative analysis of urea.

Spontaneous and background fluorescence can interfere with the detection of biological samples. Upconversion nanoparticles (UCNPs), which can eliminate the self-fluorescence and background interference of biological samples, are an effective strategy for detecting human biomarkers with high sensitivity. Researchers from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences (Beijing, China) have developed a polyacrylamide (PAM) hydrogel sensor based on an upconversion optical probe, which was composed of UCNPs and p-dimethylamino-cinnamaldehyde (p-DMAC). As a result of the internal filtration effect, the red product produced by the reaction of urea and p-DMAC quenched the green fluorescence of the UCNPs and caused the upconversion fluorescence to change from yellow to red, thus realizing the fluorescence detection of urea.

Based on this, the researchers fabricated a flexible wearable sensor by combining PAM hydrogel and a portable sensor platform built using 3D printing technology. The researchers found the limits of detection of the self-designed upconversion fluorescent probe and the hydrogel sensor to be just 1.4 μM and 30 μM, respectively, which was much lower than the urea content in sweat, implying higher sensitivity. The sensor patch design paves the way for a convenient approach to accurately detect biomarkers in body fluids and for development into a device that could provide disease warning and clinical diagnosis, according to the researchers.

Related Links:
Chinese Academy of Sciences


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.